Search

Copyright of Der Urologe A is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Purpose: Somatostatin-based radiopeptide treatment is generally performed using the β-emitting radionuclides Y or Lu. The present study aimed at comparing benefits and harms of both therapeutic approaches. Methods: In a comparative cohort study, patients with advanced neuroendocrine tumours underwent repeated cycles of [Y-DOTA]-TOC or [Lu-DOTA]-TOC until progression of disease or permanent adverse events. Multivariable Cox regression and competing risks regression were employed to examine predictors of survival and adverse events for both treatment groups. Results: Overall, 910 patients underwent 1,804 cycles of [Y-DOTA]-TOC and 141 patients underwent 259 cycles of [Lu-DOTA]-TOC. The median survival after [Lu-DOTA]-TOC and after [Y-DOTA]-TOC was comparable (45.5 months versus 35.9 months, hazard ratio 0.91, 95 % confidence interval 0.63-1.30, p = 0.49). Subgroup analyses revealed a significantly longer survival for [Lu-DOTA]-TOC over [Y-DOTA]-TOC in patients with low tumour uptake, solitary lesions and extra-hepatic lesions. The rate of severe transient haematotoxicities was lower after [Lu-DOTA]-TOC treatment (1.4 vs 10.1 %, p = 0.001), while the rate of severe permanent renal toxicities was similar in both treatment groups (9.2 vs 7.8 %, p = 0.32). Conclusion: The present results revealed no difference in median overall survival after [Lu-DOTA]-TOC and [Y-DOTA]-TOC. Furthermore, [Lu-DOTA]-TOC was less haematotoxic than [Y-DOTA]-TOC. [ABSTRACT FROM AUTHOR]

Major studies are still lacking on the impact of differing intensities of long-term donor plasmapheresis, not only on total serum protein, albumin and immunoglobulin G (IgG), but also on humoral and cellular immunity, red cell and iron metabolism, and biochemical cardiovascular risk markers. Three groups of donors, comprising 483 individuals undergoing differing intensities of long-term serial plasmapheresis, were entered into a cross-sectional study. A fourth control group consisted of 100 non-donors. In addition to measuring total protein, albumin and IgG levels, we determined parameters of humoral and cellular immunity, red cell and iron metabolism and recognized biochemical cardiovascular risk factors. The median annual net amount of plasma donated by the three donor groups was 37, 16 and 10 l, respectively ( P < 0·0001). Donors had significantly lower total serum protein, albumin and IgG levels than non-donors ( P < 0·0001), but the intensity of plasmapheresis had no influence on those parameters. Like non-donors, all plasma donors had normal humoral and cellular immunity. No increased rates of iron store depletion were observed in the three groups of plasma donors. Plasma donors were not at increased cardiovascular risk. Regular donor plasmapheresis of up to 45 l of plasma per year appears to be as safe as more moderate plasmapheresis programmes, with respect to the parameters analysed in this study. Individuals donating under these conditions did not develop impaired humoral and cellular immunity, iron store depletion, or increased cardiovascular risk with regard to established biochemical risk markers. Prospective studies are required to determine more exactly than in retrospective analyses the reasons why donors withdraw from plasmapheresis programmes. [ABSTRACT FROM AUTHOR]

Copyright of Archiv für Psychiatrie und Nervenkrankheiten is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Some processes used to passivate n-type mercury cadmium telluride photoconductive infrared detectors produce electron accumulation layers at the surfaces, which result in 2D electron gases. The dispersion relations for the electric subbands that occur in these layers have been calculated from first principles. Poisson's equation for the built-in potential and Schroedinger's equation for the eigenstates have been solved self-consistently. The cyclotron effective masses and Fermi energies have been computed for each subband density for 12 total densities between 0.1 to 5.0×10 cm. The agreement with Shubnikov-de Haas measurements is very good at lower densities with possible improvement if band-gap narrowing effects were to be included. At higher densities, larger differences occur. The simple 2D description is shown to break down as the density increases because the wave functions of the conduction and valence bands cannot be well separated by the narrow band gap of long-wavelength detectors. These results provide a basis for characterizing the passivation processes, which greatly affect device performance. [ABSTRACT FROM AUTHOR]

In rats with myotonia induced by peroral application of 20,25-diazachotesterol this substance is enriched as esters of a dehydrogenated product in the vesicles of sarcoplasmic reticulum. The isolation and purification of this product is described. Gas chromatographic analysis of the fatty acid components of this product shows that it is rich in unsaturated fatty acids especially in arachidonic acid. The double bond of the dehydrogernated steroid is located in the sidechain of the originally 20,25-diazacholesterol as is shown by mass spectrometry. This alteration of the vesicles of sarcoplasmic reticulum may be related to the observed myotonia. [ABSTRACT FROM AUTHOR]